By Mill Chart
Last update: Jul 30, 2025
Value investing focuses on finding stocks priced below their true worth while having solid financial foundations. The method, based on Benjamin Graham’s ideas, looks for firms with steady earnings, strong financial positions, and room for expansion, all at a lower price. A "Decent Value" screen picks stocks with a valuation score above 7 (showing they are undervalued) while also having good marks in earnings, financial stability, and growth. This method lowers the chance of falling into value traps by prioritizing quality along with low prices.
EXELIXIS INC (NASDAQ:EXEL) appears as a strong option under this system, earning an 8 in valuation, 9 in financial health, 8 in profitability, and 8 in growth in ChartMill’s fundamental analysis report. Here’s what makes it notable:
The stock’s valuation numbers indicate it is cheaper compared to similar companies and the wider market:
For value investors, these figures match the strategy’s main idea: buying stocks at a discount with a safety net.
EXEL’s health score of 9 shows outstanding stability and cash reserves:
A sturdy financial position is important for value investors, as it limits risk while the market adjusts to the stock’s true value.
With a profitability score of 8, EXEL shows reliable earnings strength:
High profitability confirms the company’s true worth, a key factor for value investors avoiding stocks that are cheap for poor reasons.
EXEL’s growth score of 8 points to both past and expected progress:
Growth is sometimes ignored in classic value screens, but EXEL’s mix of low price and growth potential fits newer views of value investing—where factors like earnings growth can help close the price gap.
EXELIXIS offers a unique combination of low price, financial stability, earnings strength, and growth—key parts of a good value investment. Its focus on oncology, including its main drug cabozantinib, adds growth potential that could further shrink the difference between its market price and true value.
For investors looking for similar options, check out more stocks that pass the Decent Value Stocks Screen.
Disclaimer: This analysis is not investment advice. Do your own research or talk to a financial advisor before making investment choices.
36.94
-7.45 (-16.78%)
Find more stocks in the Stock Screener